Diagnosis of Prostate Cancer Recurrence with PSA Levels below 0.2 ng/ml with Intermittent Antiandrogen Therapy
Article Sidebar
Main Article Content
Abstract
Abstract
A case of investigation of a patient with recurrent prostate cancer after Radical Prostatectomy (RP) followed with 70 Gray irradiation (RT) due to numerous positive margins is reported. The Prostate Specific Antigen (PSA) level was fluctuating below 0.2 ng/mL. Comprehensive data on symptoms, Ultrasound (US) measurements, medical treatment, and PSA level fluctuations during intermittent Antiandrogen Therapy (ADT) were analyzed. ADT led to reduction in the size of the cancer by almost half. The PSA level decreased in accordance with the ADT injections. US with Doppler showed an area with increased blood flow. A nano-knife procedure was applied to this suspicious area. Then the Pfizer vaccine was administered, as a result of the final two treatments the PSA level dropped to 0,006 ng/ml. All the symptoms disappeared.
Downloads
Article Details
Copyright (c) 2025 Grytsenko K.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing and protecting the author rights is the central aim and core of the publishing business. Peertechz dedicates itself in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. Peertechz licensing terms are formulated to facilitate reuse of the manuscripts published in journals to take maximum advantage of Open Access publication and for the purpose of disseminating knowledge.
We support 'libre' open access, which defines Open Access in true terms as free of charge online access along with usage rights. The usage rights are granted through the use of specific Creative Commons license.
Peertechz accomplice with- [CC BY 4.0]
Explanation
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
With this license, the authors are allowed that after publishing with Peertechz, they can share their research by posting a free draft copy of their article to any repository or website.
'CC BY' license observance:
|
License Name |
Permission to read and download |
Permission to display in a repository |
Permission to translate |
Commercial uses of manuscript |
|
CC BY 4.0 |
Yes |
Yes |
Yes |
Yes |
The authors please note that Creative Commons license is focused on making creative works available for discovery and reuse. Creative Commons licenses provide an alternative to standard copyrights, allowing authors to specify ways that their works can be used without having to grant permission for each individual request. Others who want to reserve all of their rights under copyright law should not use CC licenses.
Pal SK, Ruel N, Vogelzang N, Chang M, Wilson TG, Jones JO, et al. Preoperative androgen deprivation therapy for localized prostate cancer: delayed biochemical recurrence in high-risk disease. Clin Genitourin Cancer. 2014;12(3):149-54. Available from: https://doi.org/10.1016/j.clgc.2013.11.009
MacLennan S, Azevedo N, Duncan E, Dunsmore J, Fullwood L, Lumen N, Plass K, et al. Mapping European Association of Urology guideline practice across Europe: an audit of androgen deprivation therapy use before prostate cancer surgery in 6598 cases in 187 hospitals across 31 European countries. Eur Urol. 2023;83:393-401. Available from: https://doi.org/10.1016/j.eururo.2022.12.031
Bhargava P, Ravizzini G, Chapin BF, Kundra V. Imaging biochemical recurrence after prostatectomy: Where are we headed? AJR Am J Roentgenol. 2020;214(6). Available from: https://doi.org/10.2214/AJR.19.21905
Sciarra A, Santarelli V, Salciccia S, Moriconi M, Basile G, Santodirocco L, Carino D, et al. How the management of biochemical recurrence in prostate cancer will be modified by the concept of anticipation and incrementation of therapy. Cancers (Basel). 2024;16(4):764. Available from: https://doi.org/10.3390/cancers16040764
Shore ND, Moul JW, Pienta KJ, Czernin J, King MT, Freedland SJ. Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification. Prostate Cancer Prostatic Dis. 2024;27:192-201. Available from: https://doi.org/10.1038/s41391-023-00712-z
Mir MC, Li J, Klink JC, Kattan MW, Klein EA, Stephenson AJ. Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy. Eur Urol. 2014;66(2):204-10. Available from: https://doi.org/10.1016/j.eururo.2013.08.022
Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, et al. Salvage therapy for prostate cancer: AUA/ASTRO/SUO guideline part 1: introduction and treatment decision-making at the time of suspected biochemical recurrence after radical prostatectomy. J Urol. 2024;11(4):509-17. Available from: https://mdanderson.elsevierpure.com/en/publications/salvage-therapy-for-prostate-cancer-auaastrosuo-guideline-part-i